Duration of hematologic response.

Of the 85 patients in the 600-mg dose group who had sustained hematologic responses, 68 are still in response (censored) between 2.3 and 13.8 months after response was first recorded. One of these patients discontinued to undergo BMT after 5 months in CHR. Of the 40 patients in the 400-mg dose group who had sustained hematologic responses, 21 are still in response (censored) between 4.2 and 16.0 months after the first report of response. The difference between dose groups was statistically significant (P = .014, log-rank test).